Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Jiří Drahota

General University Hospital in Prague

Czech Republic

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

LinkedIn ORCID

Google Scholar

Research Interests

Virology

20%

Epidemiology

40%

Multiple Sclerosis

90%

Pharmacoepidemiology

40%

Sars-cov-2

30%

Antiviral Therapy

30%

Covid-19

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles13

COVID‐19 vaccination and relapse activity: A nationwide cohort study of patients with multiple sclerosis in Denmark

Article Link

Year:

2024

Real-world effectiveness of cladribine as an escalation strategy for MS: Insights from the Czech nationwide ReMuS registry

Article Link

Year:

2024

Big Multiple Sclerosis Data network: an international registry research network

Article Link

Year:

2024

Effectiveness of tixagevimab/cilgavimab (Evusheld) in antiCD20‑treated patients with multiple sclerosis and neuromyelitis optica spectrum disorder

Article Link

Year:

2024

Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers

Article Link

Year:

2023

Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries

Article Link

Year:

2023

Is breastfeeding in MS harmful or not? An answer from real-world Czech data

Article Link

Year:

2023

The Czech National MS Registry (ReMuS): Data trends in multiple sclerosis patients whose first disease-modifying therapies were initiated from 2013 to 2021

Article Link

Year:

2023

Corrigendum to ’To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection’[Multiple sclerosis and related disorders vol. 65 (2022) 104014] (Multiple Sclerosis and Related Disorders (2022) 65, (S2211034822005235), (10.1016/j.msard.2022.104014))

Article Link

Year:

2023

Predictors of treatment switching in the Big Multiple Sclerosis Data Network

Article Link

Year:

2023

To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection

Article Link

Year:

2022

Oral cladribine in the treatment of multiple sclerosis – data from the national registry ReMuS® registry

Article Link

Year:

2021

Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia

Article Link

Year:

2021

Collaborators12

Anna Glaser

Karolinska Institutet

SWEDEN

Ryan Ramanujam

Karolinska Institutet

SWEDEN

Michaela Tyblova

Charles University and General University Hospital in Prague, First Faculty of Medicine

CZECH REPUBLIC

Elena - Flavia Mouresan

Karolinska Institutet

SWEDEN

Peter Vestergaard Rasmussen

Associate professor

Aarhus University

DENMARK

Melinda Magyari

Associate professor

University of Copenhagen

DENMARK

Klara Novotna

CZECH REPUBLIC

Rodden Middleton

Associate Professor of Disease Registers and Health Data

Swansea University

UNITED KINGDOM

Dominika Stastna

Charles University and General University Hospital in Prague, First Faculty of Medicine

CZECH REPUBLIC

Petra Hanulikova

Charles University

CZECH REPUBLIC

Marta Vachova

Head doctor

Krajská zdravotní as Nemocnice Teplice oz

CZECH REPUBLIC

Ali Manouchehrinia

The University of British Columbia

CANADA

How do I reach out?

Meet Kite AI